

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-04 Medicare Claims Processing	Centers for Medicare & Medicaid Services (CMS)
Transmittal 1204	Date: MARCH 16, 2007
	Change Request 5517

SUBJECT: April 2007 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing File, Effective April 1, 2007, and Revisions to the January 2007 Quarterly ASP Medicare Part B Drug Pricing Files

I. SUMMARY OF CHANGES: This instruction informs Medicare contractors to download the April 2007 ASP drug pricing file for Medicare Part B drugs as well as the revised January 2007 ASP files.

New / Revised Material

Effective Date: April 1, 2007

Implementation Date: April 2, 2007

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-*Only One Per Row.*

R/N/D	Chapter / Section / Subsection / Title
N/A	

III. FUNDING:

No additional funding will be provided by CMS; contractor activities are to be carried out within their FY 2007 operating budgets.

IV. ATTACHMENTS:

Recurring Update Notification

**Unless otherwise specified, the effective date is the date of service.*

Attachment – Recurring Update Notification

Pub. 100-04	Transmittal: 1204	Date: March 16, 2007	Change Request: 5517
-------------	-------------------	----------------------	----------------------

SUBJECT: April 2007 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing File, Effective April 1, 2007, and Revisions to the January 2007 Quarterly ASP Medicare Part B Drug Pricing Files

Effective Date: April 1, 2007

Implementation Date: April 2, 2007

I. GENERAL INFORMATION

A. Background: Section 303(c) of the Medicare Modernization Act of 2003 (MMA) revised the payment methodology for Part B covered drugs that are not paid on a cost or prospective payment basis. Per the MMA, beginning January 1, 2005, the vast majority of drugs and biologicals not paid on a cost or prospective payment basis will be paid based on the average sales price (ASP) methodology. Pricing for compounded drugs is performed by the local contractor. Additionally, beginning in 2006, all ESRD drugs furnished by both independent and hospital-based ESRD facilities, as well as specified covered outpatient drugs, and drugs and biologicals with pass-through status under the OPPTS, will be paid based on the ASP methodology. The ASP methodology is based on quarterly data submitted to CMS by manufacturers. CMS will supply contractors with the ASP drug pricing files for Medicare Part B drugs on a quarterly basis.

For 2007, a separate fee of \$0.152 per I.U. of blood clotting factor furnished is payable when separate payment for the blood clotting factor is made. The furnishing fee will be included in the payment amounts on the quarterly ASP pricing files.

B. Policy:

ASP Methodology

Beginning January 1, 2005, the payment allowance limits for Medicare Part B drugs and biologicals that are not paid on a cost or prospective payment basis are 106 percent of the ASP. Beginning January 1, 2006, the payment allowance limits for all ESRD drugs when separately billed by freestanding and hospital-based ESRD facilities, as well as specified covered outpatient drugs, and drugs and biologicals with pass-through status under the OPPTS, will be paid based on 106 percent of the ASP. CMS will update the payment allowance limits quarterly. There are exceptions to this general rule as summarized below.

(1) The payment allowance limits for blood and blood products (other than blood clotting factors) that are not paid on a prospective payment basis, are determined in the same manner the payment allowance limits were determined on October 1, 2003. Specifically, the payment allowance limits for blood and blood products are 95 percent of the average wholesale price (AWP) as reflected in the published compendia. The payment allowance limits will be updated on a quarterly basis. Blood and blood products furnished in the hospital outpatient department are paid under OPPTS at the amount specified for the APC to which the product is assigned.

(2) The payment allowance limits for infusion drugs furnished through a covered item of durable medical equipment on or after January 1, 2005, will continue to be 95 percent of the AWP reflected in the published compendia as of October 1, 2003, unless the drug is compounded. The payment allowance limits will not be updated in 2007. The payment allowance limits for infusion drugs furnished through a covered item of durable medical equipment that were not listed in the published compendia as of October 1, 2003, (i.e., new drugs) are 95 percent of the first published AWP unless the drug is compounded.

(3) The payment allowance limits for influenza, Pneumococcal and Hepatitis B vaccines are 95 percent of the AWP as reflected in the published compendia except where the vaccine is furnished in a hospital outpatient department. Where the vaccine is administered in the hospital outpatient department, the vaccine is paid at reasonable cost.

(4) The payment allowance limits for drugs that are not included in the ASP Medicare Part B Drug Pricing File or Not Otherwise Classified (NOC) Pricing File, other than new drugs that are produced or distributed under a new drug application approved by the Food and Drug Administration, are based on the published wholesale acquisition cost (WAC) or invoice pricing. In determining the payment limit based on WAC, the contractors follow the methodology specified in Pub. 100-04, Chapter 17, Drugs and Biologicals, for calculating the Average Wholesale Price (AWP) but substitute WAC for AWP. The payment limit is 100 percent of the lesser of the lowest-priced brand or median generic WAC. For 2006, the blood clotting furnishing factor of \$0.146 per I.U. is added to the payment amount for the blood clotting factor when the blood clotting factor is not included on the ASP file. For 2007, the blood clotting furnishing factor of \$0.152 per I.U. is added to the payment amount for the blood clotting factor when the blood clotting factor is not included on the ASP file.

At the contractors' discretion, contractors may contact CMS to obtain payment limits for drugs not included in the quarterly ASP or NOC files or otherwise made available by CMS on the CMS Web site. If the payment limit is available from CMS, contractors will substitute CMS-provided payment limits for pricing based on WAC or invoice pricing. CMS will provide the payment limits either directly to the requesting contractor or via posting an MS Excel file on the CMS Web site.

(5) The payment allowance limits for new drugs that are produced or distributed under a new drug application approved by the Food and Drug Administration and that are not included in the ASP Medicare Part B Drug Pricing File or Not Otherwise Classified (NOC) Pricing File are based on 106 percent of the WAC, or invoice pricing if the WAC is not published. This policy applies only to new drugs that were first sold on or after January 1, 2005. At the contractors' discretion, contractors may contact CMS to obtain payment limits for new drugs not included in the quarterly ASP or NOC files or otherwise made available by CMS on the CMS Web site. If the payment limit is available from CMS, contractors will substitute CMS-provided payment limits for pricing based on WAC or invoice pricing. CMS will provide the payment limits either directly to the requesting contractor or via posting an MS Excel file on the CMS Web site. For 2006, the blood clotting furnishing factor of \$0.146 per I.U. is added to the payment amount for the blood clotting factor when the blood clotting factor is not included on the ASP file. For 2007, the blood clotting furnishing factor of \$0.152 per I.U. is added to the payment amount for a new blood clotting factor when a new blood clotting factor is not included on the ASP file.

(6) The payment allowance limits for radiopharmaceuticals are not subject to ASP. Contractors should determine payment limits for radiopharmaceuticals based on the methodology in place as of November 2003 in the case of radiopharmaceuticals furnished in other than the hospital outpatient department. Radiopharmaceuticals furnished in the hospital outpatient department are paid charges reduced to cost by the hospital's overall cost to charge ratio.

On or after March 19, 2007, the revised January 2007 ASP payment file and the April 2007 ASP file will be available for download. On or after March 19, 2007, the revised January 2007 and the April 2007 ASP NOC files will be available for retrieval from the CMS ASP webpage. The revised January 2007 payment allowance limits apply to dates of service January 1, 2007 through March 31, 2007. The April 2007 payment allowance limits apply to dates of service April 1, 2007 through June 30, 2007.

The payment limits included in the revised ASP and NOC payment files supersede the payment limits for these codes in any publication published prior to this document.

Number	Requirement	Responsibility (place an "X" in each applicable column)										
		A / B	D M E	F I	C A R R I E R	D M E R C	R H I	Shared-System Maintainers				OTHE R
								F I S S	M C S	V M S	C W F	
	Final File: MU00.@BF12390.ASP.CY07.JAN.V0319											
5517.1.5	Contractors shall overlay or manually update the previous January 2007 file with the new January 2007 ASP drug pricing file.	X	X	X	X	X	X	X	X	X		
5517.1.6	Contractors shall retrieve the revised January 2007 ASP NOC pricing file from the CMS ASP webpage on or after March 19, 2007.	X	X	X	X	X	X	X	X	X		
5517.1.7	Contractors shall use the revised January 2007 ASP and NOC drug pricing files to pay for Medicare Part B drugs effective January 1, 2007 through March 31, 2007.	X	X	X	X	X	X	X	X	X		
5517.2	Contractors shall not search and adjust claims that have already been processed unless brought to their attention.	X	X	X	X	X	X	X	X	X		
5517.3	Notification of successful receipt shall be sent via e-mail to price_file_receipt@cms.hhs.gov stating the name of the file received and the entity for which it was received (e.g., carrier/DMERC/fiscal intermediary name and number).	X	X	X	X	X	X	X	X	X		
5517.4	The ASP and NOC drug pricing files will contain the applicable payment allowance limits (i.e., 106% ASP, 106% WAC, or 95% AWP); therefore, Medicare contractors shall not make any additional payment calculations.	X	X	X	X	X	X	X	X	X		
5517.5	For any drug or biological not listed in the ASP or NOC drug pricing files, contractors shall determine the payment allowance limits in accordance with the policy described in this CR and JSM-06391.	X	X	X	X	X	X	X	X	X		
5517.5.1	FIs should seek payment allowances not on the ASP file from their local carrier for drugs and biologicals.	X		X			X	X				
5517.6	At the contractor's discretion, contractors should contact CMS to obtain payment limits for drugs not included in the quarterly ASP or NOC files or otherwise made available by CMS on the CMS Web site.	X	X	X	X	X	X					
5517.6.1	If the payment limit is available from CMS, contractors shall substitute CMS-provided payment limits for pricing, based on WAC or invoice pricing.	X	X	X	X	X	X	X	X	X		
5517.6.1.1	Contractors shall contact CMS via e-mail at sec303aspdata@cms.hhs.gov .	X	X	X	X	X	X					

Number	Requirement	Responsibility (place an "X" in each applicable column)										
		A / B	D M E	F I	C A R R I E R	D M R C	R H I	Shared-System Maintainers				OTHE R
								F I S S	M C S	V M S	C W F	
5517.6.1.2	Contractors shall include "Pricing Request" in the subject line.	X	X	X	X	X	X					
5517.7	Contractors shall use the Medicare Contractor Reporting Template for Part B drugs to report information on Medicare Part B drugs not paid on a cost or prospective payment basis when payment limits are not listed in the quarterly drug pricing ASP and NOC files, or in the OPSS Pricer.	X	X	X	X	X	X					
5517.7.1	Contractors shall use the template to report pricing information for the NOC drugs not included on the Medicare Part B NOC pricing file, any HCPCS drug codes not on the ASP file, and OPSS drugs not in the OPSS Pricer.	X	X	X	X	X	X					
5517.7.2	Contractors shall list all drugs that were priced since the last submitted report.	X	X	X	X	X	X					
5517.7.3	Contractors shall list each drug priced on the report only once, unless the drug was priced via invoice and the price is not the same.	X	X	X	X	X	X					
5517.7.4	For compounded drugs, contractors shall report the name of each drug in the compounded product that required manual pricing, each time the drug price changed.	X	X	X	X	X	X					
5517.7.5	Contractors shall prepare and submit the reports so that each report covers approximately 30 days of pricing activity.	X	X	X	X	X	X					
5517.7.6	Contractors shall report drugs omitted from previous reports in the next report.	X	X	X	X	X	X					
5517.7.7	Contractors shall complete the report in its entirety.	X	X	X	X	X	X					
5517.7.8	Carriers do not need to report radiopharmaceuticals.	X	X	X	X	X	X					
5517.7.9	FIs shall report pricing information for drugs, biologicals, and radiopharmaceuticals that are billed using C9399.	X		X			X					
5517.8	Contractors shall download the template from the CMS Web site at http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp .	X	X	X	X	X	X					
5517.9	Contractors shall complete the template on a monthly basis.	X	X	X	X	X	X					
5517.9.1	The template shall be in MS Excel format.	X	X	X	X	X	X					
5517.9.2	Contractors shall send it to sec303aspdata@cms.hhs.gov on the first business day of the month.	X	X	X	X	X	X					

IV. SUPPORTING INFORMATION

A. For any recommendations and supporting information associated with listed requirements, use the box below:

Use "Should" to denote a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:
N/A	

B. For all other recommendations and supporting information, use this space: N/A

V. CONTACTS

Pre-Implementation Contact(s): Catherine Jansto, catherine.jansto@cms.hhs.gov

Post-Implementation Contact(s): Appropriate Regional Office

VI. FUNDING

A. For Fiscal Intermediaries, Carriers, and the Durable Medical Equipment Regional Carrier (DMERC), use only one of the following statements:

No additional funding will be provided by CMS; contractor activities are to be carried out within their FY 2007 operating budgets.

B. For Medicare Administrative Contractors (MAC), use the following statement:

The contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the Statement of Work (SOW). The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.